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 Abstract 
The adult myocardium, including human, harbours a population of resident multi-potent 
cardiac stem cells (CSCs), which when stimulated under the right conditions can give rise 
to new cardiomyocytes and vasculature. Elucidation of the cellular and molecular 
mechanisms that govern CSC biology and their role in myocardial regeneration will allow 
the design and development of optimal therapeutic interventions. It is now evident that 
different growth factors and cytokines govern CSC survival, proliferation, migration and 
differentiation, as well as playing a role in activating cardiac repair mechanisms such as 
improving angiogenesis, cardiomyocyte survival and limiting fibrosis. This review article 
will summarize the evidence for a role of VEGF, NRG-1, IGF-1, HGF, EGF, FGF and TGF-β1 
in modulating the repair and regeneration of cardiac tissue. It will also discuss the use of 
exosomes and exercise training as interventions to stimulate the endogenous repair and 
regenerative mechanisms in the damaged heart.  
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1. Growth factors and cytokines that promote cardiac repair and regeneration 
Cardiac regeneration therapies need to encompass neomyogenesis, neoangiogenesis, 
scaffold/extracellular matrix integrity, and CSC survival, self-renewal and differentiation. 
In the long-term the field aims to move towards cell-free, protein-based therapies. 
Therefore, various growth factors and cytokines have been singled out as candidates for 
therapeutic cardiac regeneration. As the list of growth factors and cytokines expands so 
too does our knowledge of growth factor-mediated regenerative potential.   
1.1 Vascular endothelial growth factor (VEGF)  
VEGF is the cornerstone cytokine involved in promoting neo-vascularisation thus has been 
the focus for the treatment of heart disease [1, 2]. Initial observations in animal models 
suggested that recombinant VEGF protein administration could confer beneficial effects 
[3]. However, promising results from pre-clinical studies were not effectively translated in 
human clinical trials, where intracoronary protein administration in patients was found to 
be ineffective [4]. This is now known to be due to the short half-life of VEGF in vivo 
coupled with insufficient myocardial uptake after coronary infusion. It was thought that 
these issues could largely be overcome through delivery of the VEGF gene rather than 
protein therefore subsequent studies focused on gene therapy approaches, with pre-
clinical efforts again demonstrating improved cardiac function following gene delivery [5, 
6].  Pilot gene therapy studies targeted patients with coronary artery disease and 
demonstrated a favourable safety profile along with an improvement in cardiac function 
[7] however more-rigorously designed clinical trials, such as the EUROINJECT ONE [8] and 
NORTHERN [9], did not report any significant clinical benefit. Co-administration of VEGF 
with stem cells or genetic manipulation to increase the VEGF secretory capacity of stem 
cells were also investigated. One study delivered VEGF-A165-transfected mesenchymal stem 
cells (MSCs) into damaged rat hearts and showed a reduced infarct size, increased ejection 
fraction, and capillary density [10], whilst the MyStromalCell trial utilised VEGF-A165-
stimulated adipose-derived stromal stem cell transplantation in patients with chronic 
myocardial ischemia [11]. Delivery of VEGF-A in combination with various scaffolds have 
also achieved much greater success in stimulating angiogenesis and restoring cardiac 
function [12, 13].  Together this would strongly suggest that controlled and targeted 
delivery of VEGF needs to be further developed to achieve efficacious clinical outcomes in 
terms of improving neovascularisation. 
1.2 Neuregulin 1 (NRG-1) 
NRG-1 has been implicated in stimulating cardiac repair and regeneration [14, 15]. It is 
thought that NRG-1 imparts functional benefits by activating and increasing c-kitpos 
endogenous cardiac stem cell (CSC) proliferation [15], inducing cardiomyocyte 
replacement [16], protecting cardiomyocytes from apoptosis and improving mitochondrial 
function [17].  More recently, D'Uva et al. demonstrated that transient induction of the 
NRG-1 receptor, Erbb2 following mycardial infarction (MI) in adult mice led to improved 
heart function, reduced scarring and increased cardiomyocyte proliferation, compared 
with mice that did not receive activated Erbb2 [18].   Two Phase II human trials have 
reported that daily infusions of recombinant human NRG-1 (rhNRG-1) demonstrated 
improved and sustained hemodynamic measurements in patients with chronic heart failure 
[19, 20].  
1.3 Insulin Growth Factor 1 (IGF-1) and Hepatocyte Growth Factor (HGF)  
IGF-1 modulates multiple signaling cascades, resulting in a potent proliferative signal that 
blocks apoptosis and stimulates growth in multiple different cells and organs [21]. 
Interestingly, experimental evidence shows that reduced IGF-1 signalling in animals is 
associated with lifespan extension [22].  
 
Skeletal muscle-restricted expression of IGF-1 increased bone marrow and muscle satellite 
stem cell pools, providing evidence for its effects on cell proliferation and subsequent 
increased muscle mass in vivo [23]. Comparable findings have been reported in the heart, 
where cardiac overexpression of IGF-1 increased the abundance of c-kitpos/Sca-1pos side 
population cells (SP) in the bone marrow and CD34pos SP cells in the heart [24]. Moreover, 
IGF-1 mediated the release of cytokines involved in activating the SP cells therefore 
promoting cross-talk between the heart and bone marrow leading to increased 
capilliarisation following injury [25]. Furthermore, Santini et al. showed in post-infarcted 
mice, which express the transgene of the locally acting IGF-1 in the myocardium (mIGF-1), 
improved myocardial function, which was coupled with a modulated inflammatory 
response, increased anti-apoptotic signalling and an increased number of newly-formed 
cardiomyocytes. The origin of these newly-formed myocytes was not elucidated, but it is 
likely they are the product of endogenous CSC differentiation. We have documented that 
when c-kitpos GATA-4high CSCs are co-cultured with rat cardiomyocytes, cardiomyocyte 
survival and contractility is enhanced through a paracrine mechanism of increased IGF-1 
signalling [26]. Over-expression of myocardial IGF-1 leads to prevention of cardiomyocyte 
attrition during ageing with a concomitant increased survival and number of CSCs. This 
resulted in increased myocyte formation governed by the PI3K-Akt signalling pathway [27]. 
It is proposed that the beneficial paracrine effect of IGF-1 in the heart acts via JNK1/SirT1 
signalling [28], through interference with reactive oxygen species (ROS) generation and 
oxidative DNA damage reversal by homologous recombination [29, 30]. Elucidating the 
mechanistic role for IGF-1 in myocardial regeneration will enable the development of 
strategies to stimulate endogenous repair and regeneration in a clinical setting.  
 
HGF and its associated receptor c-met were originally identified as mediators of liver 
regeneration [31]. However, HGF has now been linked to various tissues and has reported 
mitogenic and anti-apoptotic capabilities [32]. The role of endogenous HGF in 
cardioprotection has been documented by Nakamura et al. who identified the expression 
of both HGF and c-met in cardiomyocytes and demonstrated that plasma levels of HGF 
rapidly increase in response to ischaemia/reperfusion injury.  Neutralization of HGF in vivo 
was shown to result in cardiac dysfunction, while administration of exogenous HGF 
reduced apoptosis, decreased infarct size and improved cardiac function, compared with 
controls [33, 34].   
In terms of myocardial regeneration, HGF stimulates migration, proliferation and 
differentiation of CSCs [35, 36]. We have shown that intracoronary administration of IGF-1 
and HGF, in doses ranging from 0.5 to 2µg HGF and 2 to 8µg IGF-1, 30 minutes after MI 
during coronary reperfusion in the pig triggers a regenerative response from the c-kitpos 
endogenous CSCs.  This effect is potent and produces physiologically significant 
regeneration of the damaged myocardium without the need for cell transplantation [35]. 
IGF-1/HGF, in a dose-dependent manner, improved cardiomyocyte survival, reduced 
fibrosis and cardiomyocyte reactive hypertrophy, increased CSC migration, proliferation 
and cardiomyogenic and microvasculature differentiation. These cellular changes were 
correlated with a reduced infarct size and an improved ventricular segmental contractility 
and ejection fraction at the end of the follow-up assessed by cardiac magnetic resonance 
imaging (cMRI) [35]. 
HGF mediated myocardial regeneration has also been documented through transplantation 
of human adipose tissue-derived stem cells overexpressing HGF in a rat model of MI. 
Twenty eight days after MI, results showed an increased left ventricular ejection fraction 
(LVEF) along with attenuated fibrosis and improved angiogenesis [37].  More recent 
advances in gene therapy have led to the safety and feasibility of delivering HGF (via 
adenoviral vectors) to patients with severe coronary artery disease in first-in-man clinical 
trials [38]. 
 
1.4 Epidermal Growth Factor (EGF) 
In cardiovascular biology EGF has been implicated in many biological processes including 
regulation of blood pressure, angiogenesis, neointimal hyperplasia, atherogenesis and 
cardiac remodelling [39].  In the heart, the main source and target of EGF ligands are 
endothelial and smooth muscle cells (SMCs) [40]. Transgenic mice expressing dominant 
negative epidermal growth factor receptor (EGFR) in cardiomyocytes suffered from 
cardiac hypertrophy and cardiac dysfunction [41], and mice that had a smooth muscle 
targeted deletion of EGFR, had reduced diastolic and mean blood pressures and also 
developed hypertrophy [42]. The role of EGF in modulating angiogenesis has shown that 
pre-treatment of murine bone marrow-derived stromal cells with exogenous EGF can 
promote neo-vascularization in a mouse model of hind limb ischemia [43].  EGF has also 
been implicated in the proliferation of SMCs whereby studies have shown that inhibition of 
EGFR leads to reduction in vascular smooth muscle cell (VSMC) proliferation thus reducing 
intimal hyperplasia following balloon injury in animal models [44, 45]. Despite a large 
number of pre-clinical studies on the role of EGF in cardiovascular disease modulation, 
further clarification on the role of EGF signalling in cardiovascular repair and regeneration 
are still required in order to develop effective clinical therapies. 
1.5 Fibroblast growth factor (FGF) 
The fibroblast growth factor (FGF) family can be subdivided into 22 members along with 4 
tyrosine kinase receptors [46]. FGFs are considered to be mitogens for multiple cell types 
whilst also affecting cellular differentiation, migration, and survival [47]. FGFs have been 
implicated in myocardial regeneration with FGF-1, -2 and -4 reported to promote 
angiogenesis both in vitro and in vivo [48, 49], FGF-1 and -2 to confer cardioprotective 
effects [50], and FGF-2 to promote the activation/differentiation of CSCs [51]. Evidence 
also shows that cardiac specific overexpression of FGF-1 in animal models provides 
cardioprotection at the level of the cardiomyocyte by increasing cell viability [52], and 
FGF-2 has been shown to be a crucial mediator of cardiac hypertrophy via its 
autocrine/paracrine actions [53].  
Harnessing the potential angiogenic capacity of FGFs for cardiovascular treatment has 
been the main focus of pre-clinical research to date with many studies progressing to 
advanced-phase clinical trials. Initial clinical trials focused on delivering a single 
intracoronary infusion of FGF2 to patients with coronary artery disease (CAD).  Despite 
promising initial phase I results, the FGF Initiating RevaScularization Trial (FIRST) phase II 
trial showed no significant improvement in exercise tolerance or myocardial perfusion but 
did show a trend toward symptomatic improvement at 90 days follow up [54].  Another 
promising clinical trial performed perivascular administration of sustained-release FGF-2 
capsules concomitantly to coronary artery bypass graft (CABG) and reported that patients 
had a significant reduction in angina recurrence at long term follow-up at almost 3 years 
[55].  Subsequent trials have focused on intracoronary delivery of FGF4 in CAD patients, 
which showed improved regional blood flow [56]. Like VEGF, FGF gene transfer was based 
on the use of adenoviral vectors as the gene transfer vehicle. However, further clinical 
studies using the same adenoviral system have failed to reproduce these favourable 
outcomes, with no significant differences between treatment and placebo identified. 
However, interestingly when this study was re-classified by gender this revealed that, in 
women at least, the treatment significantly improved exercise treadmill test time and 
time to angina [57].  This has subsequently led to the AWARE (Angiogenesis in Women with 
Angina pectoris who are not candidates for Revascularization) Phase III trial to study the 
gender-specific response of FGF4 in women with angina. Given that the sustained 
presence and slow release of growth factors in tissue is important for maintenance of new 
vasculature, studies which have attempted to harness the potential of FGF have suffered 
similar issues to those reported for VEGF, with these proteins suffering from short half-
lives in vivo and viral delivery systems not facilitating adequate expression for a sufficient 
length of time to achieve beneficial effects [49].  
1.6 Transforming Growth factor-β1 (TGF-β1)  
TGF-β1 is a cytokine and TGF-β signalling is known to regulate gene networks responsible 
for fibrosis, angiogenesis, cell proliferation, differentiation, migration and apoptosis [58].  
The crucial role of this cytokine in the cardiovascular system was identified when knock-
out mice were shown to have severe cardiovascular abnormalities [59].  Many years of 
investigation have now revealed that TGF-β1 plays a critical role in the pathogenesis of 
cardiac disease through modulating inflammatory and reparative responses [60, 61]. 
Considerable evidence has shown that TGF-β1 is anti-atherogenic with SMCs obtained from 
human atherosclerotic plaques shown to be defective in the TGF-β signal pathway [62]. 
TGF-β has been show to inhibit proliferation and migration of vSMCs in vitro [63], while 
inhibition of TGF-β signal results in acceleration of atherosclerosis and an unstable plaque 
phenotype in mouse models [64]. TGF-β has also been shown to maintain the balance 
between inflammation and fibrosis in atherosclerotic plaques [65].  
Despite its cardioprotective role, TGF-β1 is also a key factor involved in detrimental 
processes, with prolonged TGF-β signalling negatively affecting post-infarct myocardial 
remodelling, leading to significant cardiac hypertrophy accompanied by interstitial fibrosis 
[66].  Promisingly, inhibition of prolonged TGF-β signalling was shown to diminish post-
infarct left ventricle dilatation [67] while intracoronary expression of a transgenic 
antagonist of TGF-β1 was shown to reduce constrictive remodelling after balloon injury in 
pigs [68]. However, inhibition of TGF-β signalling at the acute phase of MI has been shown 
to exacerbate the inflammatory response resulting in more extensive myocardial injury 
[69]. Therefore while TGF-β signalling may provide an attractive target for modulation of 
cardiac remodelling, to date this has been hampered by challenges due to the unique 
biology of this signalling pathway.  An important consideration in the development of 
future therapies is that the TGF- β signalling must be controlled in tissue-specificity and 
timing. Indeed we show that CSCs treated with TGFβ1 for 4 days induces their 
differentiation into cardiomyocyte-like cells, and when TGFβ1 is removed, together with 
the supplementation of Dickkopf-related protein 1 (Dkk1), CSCs differentiate into beating 
cardiomyocytes [70] (Figure 1). 
2. Exosomes as potential candidates to stimulate endogenous cardiac regeneration 
 
In animal models of acute MI, mesenchymal stem cell (MSC) transplantation significantly 
reduces infarct size and improves myocardial perfusion [71, 72]. The cardioprotective 
effect is evident even though the cells were unable to effectively differentiate into 
cardiomyocytes and less than 6% of the cells were found in the heart 2 weeks after the 
transplantation [73, 74]. Conditioned medium of Akt-overexpressing MSCs has also shown 
similar cardioprotective effects and significantly reduced infarct size [75]. Hence the 
regenerative and cardioprotective effect of MSCs lies in the secretome of the cells and 
their paracrine abilities [76]. 
 
Exosomes are membrane-bounded vesicles that comprise a subset of the extracellular 
vesicles (EVs) secreted via the fusion of multivescicular bodies (MVBs) with the plasma 
membrane by almost every cell in the body [77]. They are approximately 70 to 150nm in 
size, are crucial for cellular communication, and help to orient the cell spatially and 
temporally [78]. They have been found to carry and secrete proteins, cytokines, growth 
factors, microRNAs (miRNAs) and other noncoding RNAs, nucleotides and metabolites. The 
intracellular processes that determine the contents of exosomes are still being studied 
[79]. Due to their cell-specific cargo and rapid uptake by cells, EVs are being studied as 
potential candidates for targeted gene and regenerative therapies.  
 
Exosomes have been found to mimic the regenerative effects of MSCs, and therefore are a 
very attractive candidate as a replacement for stem cell therapies [80]. Exosomes isolated 
from the conditioned medium of MSCs have been found to have similar regenerative 
potential and immunomodulatory properties [78]. As with MSC transplantation reducing 
fibrosis, enhancing angiogenesis, and improving cardiac function after MI, exosomes 
isolated from MSCs and transplanted intramyocardially have been shown to reduce infarct 
size and lead to neovascularization, resulting in restoration of contractile function [81]. 
Moreover, exosomes derived from Akt-modified MSCs and intravenously delivered following 
AMI in rats, significantly improved cardiac function and promoted new blood vessel 
formation [82]. Similar effects were also observed from exosomes generated from IPS-
derived cardiomyocytes [83] and cardiac progenitors derived from neonatal hearts that 
were transplanted into rat MI models [84]. Indeed, cardiac progenitor cell-conditioned 
medium has been shown to encourage tube formation of endothelial cells and to protect 
cardiomyocytes from stress [85]. Exosomes isolated from cardiac progenitor cells were 
shown to be enriched with miR210, miR-132, and miR-146a-3p, which had cardioprotective 
effects, and with miR-451/144 which promoted H9c2 myoblast survival in vitro and 
cardiomyocyte survival in vivo [86]. 
 
The exosome field is in a nascent state. Exosomes could be applied as a combinatorial 
modality to treat patients in a sustainable manner. The use of exosomes opens up the 
possibility of using donor-derived sources in an allogeneic setting without having to 
surmount immune barriers and age-related functional decline that is seen in an autologous 
setting. Nonetheless, heterogeneity based on the source and condition of the source 
material, purification challenges in a good manufacturing practice (GMP) setting for 
clinical applications, and target specificity in uptake all need to be established before 
they can be stably and suitably translated to the clinic. 
 
3. Exercise training as a myocardial regenerative therapeutic strategy  
 
The beneficial effects of a program of exercise are well documented and a growing body 
of evidence has demonstrated the safety and efficacy of vigorous exercise training in the 
treatment (and prevention) of a number of pathologies [87, 88]. Moreover, a cochrane 
review found lower all-cause mortality in patients enrolled in a 12-month exercise-based 
rehabilitation programme [89]. The effect of exercise training as a therapeutic option for 
the treatment of heart disease has also been assessed [99, 91]. Studies show no harmful 
effects of exercise training on cardiac function [92], with some reporting improved 
function [93-95]. During exercise training the normal heart undergoes beneficial 
physiological ventricular remodelling to adapt to the added workload resulting in 
increased cardiac mass, function and contractility [96, 97]. On the other hand, 
pathological cardiac remodelling is detrimental and typically associated with death of 
cardiomyocytes, fibrotic replacement, cardiac dysfunction, and increased risk of heart 
failure and sudden death. However while multiple studies have demonstrated a dose-
response relationship between exercise and cardiovascular benefit, the optimal dosage, 
intensity, frequency, and duration of exercise, remain incompletely defined and further 
randomised controlled trials are needed to support these conclusions. 
 
We have shown that intensity-controlled (relative to VO2max) treadmill exercise training 
in adult rats results in improved cardiac function and myocardial mass remodelling through 
cardiomyocyte hypertrophy, new cardiomyocyte and capillary formation [98]. The new cell 
formation is due to the activation and ensuing differentiation of the endogenous CSCs 
[98]. However the beneficial cardiac adaptations produced by 4 weeks of intensity-
controlled exercise training were lost after a similar period of de-training [99]. Moreover, 
endurance swim training in mice induced cardiomyocyte hypertrophy and renewal, which 
was dependent on a reduction in the expression of the transcription factor C/EBPβ [100]. 
Furthermore, we have followed a human subject who had previously sustained an MI and 
undertaken 14-weeks high-intensity interval training, and shown a ~40% reduction of the 
MI scar measured by cMRI [101]. Together these data support the possibility of myocardial 
repair and regeneration with exercise training.  
 
The best characterized signalling cascade responsible for mediating physiological cardiac 
growth is the IGF-1-PI3K(p110α)-Akt pathway. Indeed, increased cardiac IGF-1 expression 
and activation of the PI3K (p110α) pathway has been implicated in increased 
cardiomyocyte hypertrophy with endurance exercise in athletes [102]. We identified the 
up-regulation of neuroregulin, BMP-10, IGF-1, and TGF-β1 in the cardiomyocytes following 
high intensity treadmill exercise training. Moreover, IGF-1 and neuroregulin increased CSC 
proliferation, with the activation of their respective receptors and physiologic molecular 
signalling targets, Akt and STAT-3, respectively [98]. On the other hand, BMP-10 and TGF-
β1 stimulated differentiation of the CSCs into the three main cardiac lineages; 
cardiomyocytes, vascular smooth muscle and endothelial cells [98]. Other growth factors 
have also been identified to play a role in exercise-induced cardiac repair, such as 
elevated levels of angiogenic factor, VEGF-A, after hypoxic exercise training [103]. 
Furthermore, exercise training up-regulated NRG-1 expression to promote cardiac repair 
through endogenous regeneration in a rat MI model [104]. 
 
Taken together exercise training is a cost-effective intervention for reducing the morbidity 
and mortality of cardiovascular disease. However, as many heart failure (HF) patients may 
be unable to exercise at the high intensity dose which leads to effective adaptation and 
activation of repair mechanisms, understanding the mechanistic underpinnings of exercise 
may provide biological insights and new therapeutic approaches to promote cardiac 
regeneration and restore cardiac function. 
4. Current clinical evidence that support the use of non-invasive strategies for 
stimulating endogenous cardiac repair and regeneration 
Intensive research has resulted in considerable advances in the discovery of therapeutic 
targets related to non-invasive strategies for cardiac repair and regeneration.  To date a 
number of growth factors have been evaluated in clinical trials, which have demonstrated 
safety and potential efficacy for the treatment of heart disease [105]. The increased 
accessibility and advances in chemical modifications to enhance protein half-life in 
vivo and minimize immunogenicity have also supported the use of growth factors/ 
cytokines as therapeutic targets for heart repair [106].  However, important challenges 
still exist in terms of ensuring the reparative mechanisms of these biomolecules and 
making them clinically viable [107, 108], together this serves to guide the development of 
future growth factor formulations. Exercise training on the other hand avoids many of the 
issues involved with delivery of targeted therapeutics and has shown to provide beneficial 
effects even in the case of chronic heart failure in aged individuals [109].  Exercise 
training as a regenerative therapeutic strategy may therefore provide a cost-effective, 
practical strategy for clinical application while the more complex issues of targeted 
delivery are resolved. 
5. Summary 
This review highlights the potential of utilising growth factors, cytokines, exosomes and 
exercise training as non-invasive strategies for stimulating endogenous cardiac repair and 
regeneration mechanisms. Significant progress in understanding the stimulation, 
mobilisation and differentiation of CSCs has been made in recent years. Nonetheless, a 
more comprehensive understanding of CSC biology is required, especially in terms of their 
long term effectiveness and regenerative potential in the aged-senescent environment. 
Once this knowledge is in place we will be in a position to obtain maximal potential from 
these unique cells in a clinical setting.  
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 Figure 1. CSCs can differentiate into functionally-competent, striated cardiomyocytes 
in vitro when treated with different growth factors in a stage/sequence-specific 
manner. (a) Schematic timeline of the stage-specific protocol used for the cardiomyogenic 
differentiation of c-kitpos CSC cardiospheres. (b) Frequency of cTnI+ cells and percentage 
of beating cells (black bars) after manipulation of the TGF-β/Wnt signaling pathways 
determined by confocal microscopy and impartial observer counting, as indicated. *P < 
0.05 versus all. (c) At days 8–14, differentiated cells stain positive for the cardiomyocyte 
lineage (S-actinin, green) exhibiting sarcomeric structures (z lines and dots) and gap 
junction formation (Cnx-43, red) between cells. Scale bars, 50 μm. (d) Real-time qPCR 
analysis and PCR products after the stage-specific cardiomyocyte differentiation protocol 
revealed the change in transcripts for the markers c-kit, Tert, Nkx2.5, GATA-4, β-MHC and 
cTnI in the differentiated cells, relative to 0 day (undifferentiated cells). Data are means 
± s.d. of three assays. Figure adapted from Smith et al. 2014, Nature Protocols.  
